3SOF

 
Pluristem Ignites Technological Innovation in the Selection and Separation of Hematopoetic Stem Cells from Cord Blood for Bone Marrow Transplantation
Business Wire - December 07, 2005 07:30
Company's Use of Non-Selected MonoNuclear Cells in PluriX(TM) Bioreactor Reaps Significant Results, Low Cell Loss Ratio, a Highly Cost-Effective Process and Avoids Arduous Regulatory Approvals


HAIFA, Isreal, Dec 07, 2005 (BUSINESS WIRE) -- Pluristem Life Systems, Inc. (OTC BB:PLRS), a biotechnology company dedicated to the expansion of stem cells from umbilical cord blood to address a myriad of fatal illnesses, today announced that the Company has overcome the major industry hurdle in the selection and separation of hematopoeitic stem cells (HSC) from adult source tissue.

The methodologies used in current HSC expansion protocols apply an enrichment stage where a rare subpopulation of source cells, defined as CD34 positive cells, are selected from a large and mixed population of mononuclear cells. This process results in a substantial loss of source cells and targets a cell population that may not represent the earliest extractable population of HSC. Additionally, to the best of the Company's knowledge, there are no FDA-approved protocols for the selection of CD 34 positive cells for regular clinical use.

Pluristem has devised a method which extracts and preserves for use a much larger number of CD34 positive cells than prior methods. Pluristem's advanced approach to cell selection and separation was accomplished by using non-selected mononuclear cells (MNC) in the Company's U.S. patented three dimensional scaffolding with flow-through co-culture techniques simulating the physiological environment within the bone marrow. The efficacy of the system in expanding non-selected MNC is based upon the selective adherence of HSC and early progenitor cells from the general MNC pool to the 3-D stroma cells cultures within the bioreactor system.

Dr. Ora Burger, Vice President of Development, stated, "The existing stem cell separation and selection process is not conducive to growing industry requirements in effectively separately the largest amount of CD-34 cells requisite for expansion. Pluristem's solution sets, what we expect, to become another industry standard."

"Clearly the stem cell selection and separation process has been reinvented through Pluristem's new process - bountiful with benefits that involve the availability of cells for expansion that could positively impact the lives of seriously ill patients, the "open"-ended non-regulatory guided process, and long term per-patient cost efficiencies of scale," added Zami Aberman, CEO.

About Pluristem

Pluristem strives to become a leading biopharmaceutical company developing, producing and marketing stem cell products for cell regenerative therapy. Pluristem's platform for expanding stem cells offers breakthrough technology and multiple product opportunities in many therapeutic areas.

For more information, visit the Company's website at: www.pluristem.com.

Safe Harbor Statement

This press release contains statements, which may constitute "forward-looking statements". Those statements include statements regarding the intent, belief or current expectations of Pluristem Life Systems, Inc., and members of our management as well as the assumptions on which such statements are based. Forward-looking statements in this release include statements regarding the company having overcome the major industry hurdle in the selection and separation of HSC from adult source tissue; that our solution may become an industry standard; and that our solution has benefits that involve the availability of cells for expansion that could positively impact the lives of seriously ill patients, the "open"-ended non-regulatory guided process, and long term per-patient cost efficiencies of scale . Actual outcomes and our actual results could differ materially from those in such forward-looking statements, as we may find that other methods may be invented that are superior to ours, we may find that there are serious side effects to our method, or our expected benefits cannot materialize because of increased costs, regulatory hurdles or inability to fund product development. As well, our products may never develop into useful products and even if they do, they may not be approved for sale to the public. For further risk factors see the Company's latest 10-KSB filed with the SEC.

SOURCE: Pluristem Life Systems, Inc.

 

Finally had come up off bottom several days ago on good vol.

Today, news came out bringing in highest vol. ever.

G-spot hit several days ago at .0248, and retested today,with a high of .025.
There are several res. points on the way up...but, looks pretty interesting.

Not in yet...still watching for now, but i may go for it soon.

GLTA


Monday, October 16 2006 7:31 AM, EST

Pluristem Pre-Clinical Results: Placenta Expanded Cell Therapy Product Increases Umbilical Cord Blood Engraftment up to 500% in Bone Marrow Transplants


HAIFA, Israel--(BUSINESS WIRE)--

Pluristem Life Systems, Inc. (OTCBB: PLRS), a cell therapy company dedicated to the commercialization of stem cell products, announces promising final results of an animal model study which could benefit 100,000 blood cancer patients annually. PLX-I, the Company's innovative adjuvant cell therapy product is based on Placenta Expanded Mesenchymal cells. It intended to resolve the global shortfall of matched tissue for blood cancer patients requiring bone marrow transplantation by improving the engraftment of Umbilical Cord Blood (UCB). The Pre-Clinical results document that adding Pluristem's PLX-I to UCB stem cells during the Bone Marrow Transplant (BMT) human cell engraftment in NOD SCID mice showed up to a 500% increased engraftment after irradiation and Chemotropic treatment.

BMT traditionally treats patients whose bone marrow has been damaged by chemotherapy, or certain genetic diseases that lead to anemia, leukemia, lymphomas, autoimmune disease and other blood-related disorders. Its effectiveness is severely limited because of the lack of a matching donor or shortage of UCB stem cells engrafted during the procedure. If additional animal studies and human clinical trials prove equally successful as this first Pre-Clinical, Pluristem's PLX-I product with 500% increased engraftment could lead to more Bone Marrow Transplants (BMT) for these types of blood cancers.

The animal studies were performed on immune-deficient NOD SCID mice following systemic myeloablation of their bone marrow to simulate the BMT clinical protocol. This in-vivo model is based on the known ability of human Hematopoietic Stem Cells (HSC) to engraft in mouse bone marrow and to simulate the recovery of the human's Hematological system. 50,000-100,000 human UCB derived CD34+ cells (hUCB CD34+) were injected into the tail vein of NOD-SCID mice along with 0.5*106 PLX I cells. After periods of 28-32 days, mice were sacrificed and the marrow was analyzed. Human cell engraftment was performed in both sub lethally irradiated (350 Rad) and chemotherapy administrated (50 mg/kg Busulfan) mice. FACS analysis of human CD45 positive cells in mice bone marrow demonstrated an increscent of cell engraftment in part of the experimental animals up to 5 folds compared to mice transplanted with CD34+ cells only.

Mr. Zami Aberman, CEO, stated, "Co-transplantation of PLX-I cell types may be a promising manipulation improving cord blood performance during the bone marrow transplants in adults blood disorder. The pre-clinical results suggest blood disorder treatment is being improved by using MSC derived from placenta and expanded in Pluristem's 3D bioreactor in combination with UCB derived HSC. We strongly believe that PLX-I can change the clinical process now being used to treat blood cancer and could eventually save millions of lives."

About Pluristem

Pluristem Life Systems, Inc. is a life sciences driven company that is developing and commercializing stem cell expansion technology products for the treatment of severe blood disorders. The Company is discovering and developing cell-based therapeutics that utilizes adult stem cells expanded in a proprietary bioreactor mimicking different naturally occurring physiological environments. Pluristem expects its first products to be cell grafts that will provide an efficient and superior alternative to the standard procedure of bone marrow transplantation. Its first adult stem cell product targets a critical global shortfall of matched tissue for bone marrow transplantation since bone marrow transplantation is often the only cure for patients suffering from leukemia, lymphoma, myeloma and many other hematological diseases. The Company has made a strategic decision to work only with adult stem cells since the practical use of embryonic stem cells is severely restricted by various religious, ethical and legal considerations.

8-k also out, check that first concerning cd's i believe.


glta

only about 10mil shares to eat through wich is nothing and kaboom...big break out over .10 coming imo

Hey dmxbr9,

seems to have gone thru much of those cds i guess...stock hit gspot again and ran to hod of .0303 so far.

Looks good...i love my g-spots!

glta

julia

Looking good!

Quote from: gmarc66 on October 17, 2006, 01:50:49 PM
seems to have gone thru much of those cds i guess...stock hit gspot again and ran to hod of .0303 so far.

Looks good...i love my g-spots!

i got my eye on this puppy. That little G looked alright, but i'm waiting for the climax of this story with a possible G-pattern development starting with the last two huge volume spikes

-fous

Hey Fous....it did already hit a g-spot....that first little vol. spike on Oct 5th was the largest vol day ever at that time. Now, yes, we have had higher vol than that these last couple of days, which could be setting up for a 2nd gpattern to follow thru.

Glta

Wednesday, October 18 2006 7:30 AM, EST

Pluristem Upgrades Manufacturing Facilities to Enable Production of First Biological Product for Phase I Clinical Trials

HAIFA, Israel--(BUSINESS WIRE)--

Pluristem Life Systems, Inc. (OTCBB: PLRS) announces they have completed upgrading and restructuring their manufacturing facilities to enable the production of their first biological product PLX-I for Phase I clinical trials. The manufacturing facilities include thirteen units of 7000 square feet total and include five clean room units of 3000 square feet total. Upon FDA approval, the facilities could support production and shipping of up to 50 doses of PLX-I per day worth more than $500,000.

Zami Aberman, Pluristem CEO states, "PLX-I can be used for the treatment of blood disorders and it could also be helpful in additional clinical indications like autoimmune disorders or cardiovascular diseases. It is a very valuable product and we have made a strategic decision to control the production in-house. Handling the product ourselves gives us a distinct advantage when these cross application situations arise. And we have further determined that to assist us in successful Phase I clinical trials and the ultimate approval by the FDA, we have upgraded and restructured as a GMP Compliance facility. GMP Compliance is a set of regulations set forth by the FDA to help ensure that various products for human use are safe and effective. GMP regulations address sanitation, process validation, equipment and document traceability, and personnel qualification. We are also working to become completely GMP compliant to further assure the future successful production and market acceptance of PLX-I."

About Pluristem

Pluristem Life Systems, Inc. is a life sciences driven company that is developing and commercializing stem cell expansion technology products for the treatment of severe blood disorders. The Company is discovering and developing cell-based therapeutics that utilizes adult stem cells expanded in a proprietary bioreactor mimicking different naturally occurring physiological environments. Pluristem expects its first products to be cell grafts that will provide an efficient and superior alternative to the standard procedure of bone marrow transplantation. Its first adult stem cell product is intended to target a critical global shortfall of matched tissue for bone marrow transplantation since bone marrow transplantation is often the only cure for patients suffering from leukemia, lymphoma, myeloma and many other hematological diseases. The Company has made a strategic decision to work only with adult stem cells since the practical use of embryonic stem cells is severely restricted by various religious, ethical and legal considerations.

    www.pluristem.com

If PLRS can clear .03 I think it may fly!

.028 now

close at 0.029


There is reason for PLRS to go higher with the recent news and upcoming presentation at Bio Europe. Most notably, the 424B4 filing reveals that 1/3 of the shares recently registered are underlying purchase warrants at 0.075 and 0.077 per share.

The company will receive the proceeds from the exercise of these warrants free and clear and has every incentive to do so, whereas the proceeds from the resale of common stock went to the selling security holders, removing overhanging debt.
Fullfilling the obligations to the CD holders was the first step in setting the stage to move forward. Once PLRS reaches the 0.10 area, approximately $4,349,881.00 will be added to the company's working capital, as per the filing I will make referrence to.

This would be where many would expect the PPS to head towards, based on how these financings work. The timing of recent news and upcoming presentations suggests that this financing is being well executed.

When reading the disclaimers from Shazaam and Lebed, we see that they were not compensated by the company itself, but by one of the selling security holders, Zegal & Ross Capital, a total of $50k cash and no shares. The filings reveal that Zegal & Ross only directly hold 1.4 million shares. Since Lebed wasn't compensated in shares, he has little reason to keep promoting PLRS unless he has reason to believe it's going much higher. He is putting his reputation and livelihood at stake.

Ask yourselves how high PLRS would need to go to make money on 1.4 million shares after paying out $50k.....The answer is it would have to be a multi bagger from here.

The options granted to management are at 0.10 per share indicating we won't see any sales from then for quite some time. There will be many alerts and talk about PLRS in the coming weeks, and it has been hinted there will be some good news coming from them in the very near term. We will see targets and chatter, but the important indicators are in the filings.


http://tinyurl.com/yymmvj


PLRS stands to gain the most above .075 per share now that they have removed $3M in convertible debt and would want to get the purchase warrants into play, as the next round of cash infusion comes without further obligation.








"Wouldn't miss it for the world, although I do play to Retire in 3-6 months and raise Throughbred horses."

Rufus Paul Harris
- July 20th 2006

Higher lows with impressive volume.  Finding support at the 13 DMA and closing above the 50 DMA.  Any thoughts from the TA guys?

Interesting move this one has been making lately.  Could be one to watch...

Volume seems to be picking up. Good day again for PLRS up 8%.

25%up without any news today....
Charts look good,only volume is little small